Despite the influx of recent, positive news from Bristol-Myers Squibb, CEO Lamberto Andreotti remained a bit cagey during today’s JP Morgan presentation about the company’s plan this year to recover from major drugs like Abilify and Baraclude going off-patent.
The past three weeks alone have been quite bullish for the pharma giant: With the “earlier-than-expected” approval of Opdivo for lung cancer – it performed well enough to cut clinical studies short.
He added that BMS has “aggressive plans” for adding more preclinical immuno-oncology assets over the next 12-24 months. It’s also working on purportedly strong early stage monoclonal antibody clinical assets: Urelumab, lirilumab and anti lag-3 monotherapy and combination regimens.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
And the R&D doesn’t end at immuno-oncology: It’s focused on hematologic malignancies, virology – particularly with HIV and HPV – and has initiated a number of programs centered on fibrosis. While the company’s main focus is on small molecules and biologics, Andreotti said, its research arem is focused on a number of platforms – particularly antibody drug conjugates.
“2015 is a very important year for the company; we’re very confident in the future,” Andreotti said.
But this is all he had to say about the off-patent BMS assets, which should take quite the revenue toll:
“Obviously in the short term we’ll lose exclusivity of Abilify and Baraclude, and we’ll lose a full year of impact – so our portfolio will continue to transform,” Andreotti said.